Key dates and figures

Eric Panijel appointed CEO of the Group.
Arkopharma celebrates its 40th anniversary. From 1980, we have been transforming the intelligence of nature into effective health solutions, combining science, controlled origin and perfect safety. And we intend to continue growing alongside you. Thank you for your trust and loyalty!

Hughes Witvoet appointed CEO of the Group.

Acquisition of its Portuguese distributor, DISTRIFA.
11^th largest company in terms of employees.
16^th company based on total turnover.
5^th company in the “natural and synthetic chemistry” sector.

Jacques Chevallet appointed CEO of the Group.
Arkopharma celebrated its 35-year anniversary.
Industrial investment relaunched on our Carros site.

Acquisition by Montagu Private Equity in July 2014, a new shareholder and a new partner.

2013 was characterized by solid growth in France and abroad.
Arkopharma signed its ESR charter (Fair Trade, Solidarity and Responsibility).

Return to growth for Arkopharma.

Merger of sales networks in France: a strategic choice to enhance customer relations and satisfaction.

Arkopharma took itself off the stock market
Action plan to improve the Group’s operating margins,
with a decision to reduce the product portfolio and launch an ambitious advertising campaign to boost the Group’s flagship products.

Launch of 4.3.2.1. SLIM CHRONO, Day and Night, in capsule form with RTC, a major formulation innovation providing 12-hour action.

Global success of 4.3.2.1. SLIM®, which became the world No. 1.

Acquisition of two new subsidiaries in Switzerland: PAD and Phyto Pharma Medika.
Success of 4.3.2.1. Slim in France, a slimming aid drink with 10 plant extracts.

Resounding success of the Group’s leading product: PHYTO SOYA® (menopause-related discomfort).

Acquisition of the Belgian distributor and creation of a subsidiary in the Netherlands. Opening of a new factory in Ireland. Transformation into a company with a Management Board and Supervisory Board.

Arkopharma became the first pharmaceutical laboratory to launch a 100% plant-based capsule.  Extremely high international growth rate (+ 50%). Sales abroad represented 31% of consolidated sales.

Listed on the “Second Market” of the Paris Stock Exchange.

Arkopharma created four subsidiaries abroad:  Spain, Italy, USA, UK.

The French Ministry of Health officially recognized phytotherapy as a branch of medicine, and put forward a proposal aimed at regulating  marketing authorizations for plant-based pharmaceutical products. Arkopharma obtained its first marketing authorizations with the “medication” classification.

Arkopharma took an innovative approach to the manufacture of its plant-extract powders and set up a cryogenic grinding system, which enabled all the active ingredients extracted from plants to be fully preserved in the final product.

Creation of Arkopharma Laboratories, pharmaceutical laboratories.
Arkopharma brought its Arkogélules® onto the market: capsules containing total plant extract powder.